Smith & NephewSNN +2.20%86 FCF Margin % is 18.58% as of Dec. 2025, which is 75% above its 10-year median of 10.61. GuruFocus rates SNN with a GF Score™ of 86/100 and a GF Value™ of $31.44 (Fairly Valued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Smith & Nephew ranks better than 82.45% on this metric.
The historical rank and industry rank for Smith & Nephew's FCF Margin % or its related term are showing as below:
SNN'
s FCF Margin % Range Over the Past 10 Years
Min: 2.11 Med: 10.61 Max: 14.98
Current: 13.82
During the past 13 years, the highest FCF Margin % of Smith & Nephew was 14.98%. The lowest was 2.11%. And the median was 10.61%.
SNN's FCF Margin % is ranked better than 82.45% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs SNN: 13.82
Smith & Nephew FCF Margin % Related Terms
Smith & Nephew FCF Margin % Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Smith & Nephew's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smith & Nephew (SNN) has a FCF Margin % of 18.58% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Smith & Nephew and its competitors. This is 75% above median its historical median of 10.61. Over the past decade, Smith & Nephew's FCF Margin % has ranged from 2.11 to 14.98. According to the industry distribution chart, Smith & Nephew ranks #143 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 17.5%.
Is Smith & Nephew's FCF Margin % too high?
Smith & Nephew's current FCF Margin % of 18.58% is 75% above median its 10-year median of 10.61. Over the past 10 years, this metric has ranged from a low of 2.11 to a high of 14.98. Based on the distribution chart, Smith & Nephew ranks #143 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Smith & Nephew has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #143 out of 815 companies for FCF Margin %. This places Smith & Nephew in the top 18% of its industry — outperforming the majority of peers. Historically, Smith & Nephew's own FCF Margin % has ranged from 2.11 to 14.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Smith & Nephew and its competitors. Smith & Nephew's current FCF Margin % is 18.58%, which is 75% above median its own 10-year median of 10.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (SNN) is currently considered Fairly Valued. The stock's GF Value™ is $31.44, compared to a current price of $30.26 — trading 3.8% below its estimated fair value. The current FCF Margin % is 18.58%, which is 75% above median its 10-year median of 10.61. Smith & Nephew's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Smith & Nephew (SNN), the current FCF Margin % is 18.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (SNN) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of $30.26 is trading 3.8% below its estimated GF Value™ of $31.44.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for SNN:
FCF Margin %: 18.58% (75% above median its 10-year median of 10.61)
GF Value™: $31.44 vs. price of $30.26 (3.8% below fair value)
No single metric tells the full story. See the SNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
86GF Score
Get the complete analysis for SNN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNN has been successfully added to your 
